Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Giladi

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Muscle & Nerve|May 8, 2000
Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's diseaseN Giladi, E S Simon, A D Korczyn, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 16, 2000
Risk factors for dementia, depression and psychosis in long-standing Parkinson's diseaseN Giladi, T A Treves, D Paleacu, et al.
Acta Neurologica Scandinavica|September 16, 2011
Vasomotor reactivity as a predictor for syncope in patients with orthostatismA Y Gur, E Auriel, A D Korczyn, et al.
Neurology|April 25, 2008
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onsetZ Gan-Or, N Giladi, U Rozovski, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1993
Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndromeS Przedborski, S Goldman, M Levivier, et al.
Gait & Posture|November 3, 2017
Age-associated changes in obstacle negotiation strategies: Does size and timing matter?I Maidan, S Eyal, I Kurz, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|March 23, 2001
Freezing of gait in patients with advanced Parkinson's diseaseN Giladi, T A Treves, E S Simon, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 17, 1997
Globus pallidus internus pallidotomy for generalized dystoniaA M Lozano, R Kumar, R E Gross, et al.
Parkinsonism & Related Disorders|September 14, 2020
Which obstacle attributes place additional demands on higher-level cognitive function in patients with Parkinson's disease?T Sharon, I Kurz, H Bernad-Elazari, et al.
Clinical Neuropharmacology|September 29, 2001
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopaJ M Rabey, I Sagi, M Huberman, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Muscle & Nerve|May 8, 2000
Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's diseaseN Giladi, E S Simon, A D Korczyn, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 16, 2000
Risk factors for dementia, depression and psychosis in long-standing Parkinson's diseaseN Giladi, T A Treves, D Paleacu, et al.
Acta Neurologica Scandinavica|September 16, 2011
Vasomotor reactivity as a predictor for syncope in patients with orthostatismA Y Gur, E Auriel, A D Korczyn, et al.
Neurology|April 25, 2008
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onsetZ Gan-Or, N Giladi, U Rozovski, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1993
Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndromeS Przedborski, S Goldman, M Levivier, et al.
Gait & Posture|November 3, 2017
Age-associated changes in obstacle negotiation strategies: Does size and timing matter?I Maidan, S Eyal, I Kurz, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|March 23, 2001
Freezing of gait in patients with advanced Parkinson's diseaseN Giladi, T A Treves, E S Simon, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 17, 1997
Globus pallidus internus pallidotomy for generalized dystoniaA M Lozano, R Kumar, R E Gross, et al.
Parkinsonism & Related Disorders|September 14, 2020
Which obstacle attributes place additional demands on higher-level cognitive function in patients with Parkinson's disease?T Sharon, I Kurz, H Bernad-Elazari, et al.
Clinical Neuropharmacology|September 29, 2001
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopaJ M Rabey, I Sagi, M Huberman, et al.
Pageof 12